Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247205628> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2247205628 endingPage "5054" @default.
- W2247205628 startingPage "5054" @default.
- W2247205628 abstract "5054 Background: Chemoradiotherapy with weekly Cp has become standard for ACC treatment. Combining Cp with another active drug in ACC such as Ir may increase the activity of Tt. Methods: Treatment consisted of 6 weekly cycles with escalating dose of Ir and fixed dose of Cp (20 mg/m 2 ) administered during pelvic radiotherapy (45–50 Gy). Brachytherapy and/or surgery were allowed after pelvic chemoradiotherapy according to center policy. Cohorts of 3 to 6 pts with FIGO stage IB-IVA newly diagnosed ACC, performance status ECOG 1–2 and adequate major organ function were eligible at each dose level. Results: 15 pts were accrued at dose level I (n = 6), II (n = 3) and Intermediate (Int) (n = 6). Dose levels (DL) for Ir were 30 mg/m 2 (I), 40 (II) and 35 (Int). Dose limiting toxicity (DLT) was observed in 2/3 pts at DL II (Gr 3 asthenia in 2/3 pts including Gr 3 diarrhea and abdominal pain in one). DLT was observed in 2/6 pts at DL I (NCI-CTC Gr 3 diarrhea in 2/6 pts including Gr 3 asthenia and abdominal pain in one) and DL Int (Gr 3 asthenia in 2/6 pts including febrile neutropenia in one). However, 3/4 pts without DLT at DL Int did not complete the whole chemotherapy schedule due to pelvic mucositis and skin toxicity (dose reduction: 2pts, early stopping at 3 cycles : 1 pt). In contrast, 5/6 non-progressive pts at DL I completed their scheduled chemo-radiotherapy, with dose reduction in only 1 pt who experienced a DLT. Efficacy evaluation showed complete and partial response in 6 and 5 of the 12 evaluable patients. Conclusions: the recommended dose for future phase II study of chemoradiotherapy in ACC is irinotecan (30mg/m 2 , weekly) with cisplatin (20 mg/m 2 , weekly). No significant financial relationships to disclose." @default.
- W2247205628 created "2016-06-24" @default.
- W2247205628 creator A5004452040 @default.
- W2247205628 creator A5013462797 @default.
- W2247205628 creator A5015076102 @default.
- W2247205628 creator A5016083775 @default.
- W2247205628 creator A5058001432 @default.
- W2247205628 creator A5070305973 @default.
- W2247205628 creator A5073063132 @default.
- W2247205628 creator A5083198792 @default.
- W2247205628 creator A5086083902 @default.
- W2247205628 date "2006-06-20" @default.
- W2247205628 modified "2023-09-28" @default.
- W2247205628 title "Phase I study of irinotecan (Iri) and cisplatin (Cp) in combination with pelvic radiotherapy for the treatment (Tt) of advanced cervical cancer (ACC): A GINECO trial" @default.
- W2247205628 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.5054" @default.
- W2247205628 hasPublicationYear "2006" @default.
- W2247205628 type Work @default.
- W2247205628 sameAs 2247205628 @default.
- W2247205628 citedByCount "0" @default.
- W2247205628 crossrefType "journal-article" @default.
- W2247205628 hasAuthorship W2247205628A5004452040 @default.
- W2247205628 hasAuthorship W2247205628A5013462797 @default.
- W2247205628 hasAuthorship W2247205628A5015076102 @default.
- W2247205628 hasAuthorship W2247205628A5016083775 @default.
- W2247205628 hasAuthorship W2247205628A5058001432 @default.
- W2247205628 hasAuthorship W2247205628A5070305973 @default.
- W2247205628 hasAuthorship W2247205628A5073063132 @default.
- W2247205628 hasAuthorship W2247205628A5083198792 @default.
- W2247205628 hasAuthorship W2247205628A5086083902 @default.
- W2247205628 hasConcept C121608353 @default.
- W2247205628 hasConcept C126322002 @default.
- W2247205628 hasConcept C126894567 @default.
- W2247205628 hasConcept C141071460 @default.
- W2247205628 hasConcept C2776694085 @default.
- W2247205628 hasConcept C2777063308 @default.
- W2247205628 hasConcept C2778220009 @default.
- W2247205628 hasConcept C2778424827 @default.
- W2247205628 hasConcept C2778496288 @default.
- W2247205628 hasConcept C2780259306 @default.
- W2247205628 hasConcept C509974204 @default.
- W2247205628 hasConcept C526805850 @default.
- W2247205628 hasConcept C71924100 @default.
- W2247205628 hasConcept C90924648 @default.
- W2247205628 hasConceptScore W2247205628C121608353 @default.
- W2247205628 hasConceptScore W2247205628C126322002 @default.
- W2247205628 hasConceptScore W2247205628C126894567 @default.
- W2247205628 hasConceptScore W2247205628C141071460 @default.
- W2247205628 hasConceptScore W2247205628C2776694085 @default.
- W2247205628 hasConceptScore W2247205628C2777063308 @default.
- W2247205628 hasConceptScore W2247205628C2778220009 @default.
- W2247205628 hasConceptScore W2247205628C2778424827 @default.
- W2247205628 hasConceptScore W2247205628C2778496288 @default.
- W2247205628 hasConceptScore W2247205628C2780259306 @default.
- W2247205628 hasConceptScore W2247205628C509974204 @default.
- W2247205628 hasConceptScore W2247205628C526805850 @default.
- W2247205628 hasConceptScore W2247205628C71924100 @default.
- W2247205628 hasConceptScore W2247205628C90924648 @default.
- W2247205628 hasIssue "18_suppl" @default.
- W2247205628 hasLocation W22472056281 @default.
- W2247205628 hasOpenAccess W2247205628 @default.
- W2247205628 hasPrimaryLocation W22472056281 @default.
- W2247205628 hasRelatedWork W1979599244 @default.
- W2247205628 hasRelatedWork W1981265379 @default.
- W2247205628 hasRelatedWork W2048191766 @default.
- W2247205628 hasRelatedWork W2091608320 @default.
- W2247205628 hasRelatedWork W2102871905 @default.
- W2247205628 hasRelatedWork W2359686091 @default.
- W2247205628 hasRelatedWork W2384708512 @default.
- W2247205628 hasRelatedWork W2463964861 @default.
- W2247205628 hasRelatedWork W2997709950 @default.
- W2247205628 hasRelatedWork W3128748660 @default.
- W2247205628 hasVolume "24" @default.
- W2247205628 isParatext "false" @default.
- W2247205628 isRetracted "false" @default.
- W2247205628 magId "2247205628" @default.
- W2247205628 workType "article" @default.